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Abstract: Prodrug activator gene therapy mediated by murine leukemia virus (MLV)-based 25 
retroviral replicating vectors (RRV) was previously shown to be highly effective in killing glioma 26 
cells both in culture and in vivo. To avoid receptor interference and enable dual vector co-infection 27 
with MLV-RRV, we have developed another RRV based on gibbon ape leukemia virus (GALV) that 28 
also shows robust replicative spread in a wide variety of tumor cells. We evaluated the potential of 29 
GALV-based RRV as a cancer therapeutic agent by incorporating yeast cytosine deaminase (CD) 30 
and E. coli nitroreductase (NTR) prodrug activator genes into the vector. The expression of CD and 31 
NTR genes from GALV-RRV achieved highly efficient delivery of these prodrug activator genes to 32 
RG-2 glioma cells, resulting in enhanced cytotoxicity after administering their respective prodrugs 33 
5-fluorocytosine and CB1954 in vitro. In an immune-competent intracerebral RG-2 glioma model, 34 
GALV-mediated CD and NTR gene therapy both significantly suppressed tumor growth with 35 
CB1954 administration after a single injection of vector supernatant. However, NTR showed greater 36 
potency than CD, with control animals receiving GALV-NTR vector alone (i.e., without CB1954 37 
prodrug) showing extensive tumor growth with a median survival time of 17.5 days, while animals 38 
receiving GALV-NTR and CB1954 showed significantly prolonged survival with a median survival 39 
time of 30 days. In conclusion, GALV-RRV enabled high-efficiency gene transfer and persistent 40 
expression of NTR, resulting in efficient cell killing, suppression of tumor growth, and prolonged 41 
survival upon CB1954 administration. This validates the use of therapeutic strategies employing 42 
this prodrug activator gene to arm GALV-RRV, and opens the door to the possibility of future 43 
combination gene therapy with CD-armed MLV-RRV, as the latter vector is currently being 44 
evaluated in clinical trials. 45 
 46 
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1. Introduction 50 
Glioblastoma multiforme (GBM) is the most frequent form of primary malignant brain tumor in 51 
adults [1], and it tends to aggressively invade the surrounding brain tissue so as to make complete 52 
surgical resection virtually impossible. Clinical trials of GBM gene therapies using a conventional 53 
replication-defective retroviral vector encoding Herpes simplex virus thymidine kinase with 54 
subsequent administration of the prodrug ganciclovir did not achieve any improvement in patient 55 
survival [2], which was attributed to extremely low levels of tumor transduction. Replication-56 
competent viral vectors enable enhanced tumor transduction levels, since these viral vectors can 57 
replicate and multiply after the initial infection event, and each infected tumor cell in effect becomes 58 
a viral vector producer cell [3-8]. We and others have previously shown that amphotropic murine 59 
leukemia virus (MLV)-based retroviral replicating vectors (RRV) achieve highly efficient and tumor-60 
selective gene transfer to glioma cells both in culture and in vivo [9-11]. Furthermore, intracerebral or 61 
intravenous injection of MLV-RRV resulted in little or no detectable infection in the normal brain or 62 
extracerebral tissues [12-14]. Early phase clinical studies of RRV-mediated prodrug activator gene 63 
therapy have shown highly promising results in recurrent high-grade glioma patients [15,16], and an 64 
international phase III trial is currently on-going. 65 
Highly efficient and tumor-selective gene transfer achieved by RRV enables efficacious prodrug 66 
activator gene therapy, which involves expression of enzymes that can convert precursor prodrugs 67 
into active chemotherapeutic drugs within the transduced tumor cells. This essentially forces the 68 
tumor to self-generate the chemotherapy drug from within. However, due to the relatively restricted 69 
payload capacity of RRV, which can only accommodate approximately 1.3-kb of additional transgene 70 
sequence inserted into the full-length replication-competent viral genome, it has generally been 71 
difficult to insert more than a single therapeutic gene per vector. For prodrug activator gene therapy, 72 
this is the equivalent of single-agent chemotherapy generated directly within the tumor. 73 
Analogously, since combination chemotherapy with multiple drugs is generally more 74 
efficacious than single-agent chemotherapy, there may be potential to achieve greater efficacy if 75 
multiple RRV encoding different prodrug activator genes could be combined. However, in this case 76 
the retrovirus envelope sequence in different vectors may need to be varied, so that these vectors do 77 
not compete for the same cell surface receptor, a phenomenon which in retrovirology is classically 78 
described as “receptor interference”. In particular, MLV-RRV currently in clinical development 79 
expresses the MLV 4070A strain amphotropic envelope, which binds the ubiquitous inorganic 80 
phosphate transporter, PiT-2 [17]. In contrast, gibbon ape leukemia virus (GALV) envelope enables 81 
cellular entry through another member of the same phosphate transporter family, PiT-1, and 82 
accordingly we have developed GALV-based RRV which also appears to show robust replicative 83 
spread in a wide variety of cancer cell lines [18-22]. 84 
To evaluate the potential of GALV-RRV as a therapeutic agent for glioma therapy, we 85 
incorporated the yeast cytosine deaminase (CD) [23] or E. coli nitroreductase (NTR) [24,25] prodrug 86 
activator genes into this type of vector. The CD enzyme converts 5-fluorocytosine (5-FC) to the highly 87 
toxic metabolite 5-fluorouracil [26], which is a potent antineoplastic agent routinely used in cancer 88 
therapy. The NTR enzyme converts 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) to a 4-89 
hydroxylamino derivative that is subsequently converted into a potent cytotoxic bifunctional 90 
alkylating agent [27]. 91 
To explore the use of GALV-RRV for prodrug activator gene therapy of glioma, in these studies 92 
we used an immune-competent rodent model of intracerebral glioma to examine tumor growth as 93 
well as survival after intracerebral inoculation of GALV-RRV carrying CD and NTR genes, followed 94 
by treatment with their respective prodrugs. We evaluated whether the high transduction level and 95 
persistent gene expression achieved by GALV-RRV has the potential to enhance the efficacy of 96 
prodrug activator gene therapy. 97 
 98 
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2. Results 99 
2.1. GALV-RRV achieves highly efficient transgene delivery to glioma cells. 100 
As previously described, the GS4-GFP vector contains a wild-type GALV provirus into which 101 
an internal ribosome entry site (IRES)-green fluorescent protein (GFP) gene expression cassette has 102 
been inserted precisely between GALV env and the 3’ untranslated region (UTR) [28] (Figure 1). To 103 
examine the ability of GS4-GFP to replicate in glioma cells in culture, we infected human (U-87) and 104 
rat (RG-2, CNS-1) glioma cells with the viral vector at low multiplicities of infection (MOI) and 105 
confirmed by flow-cytometric analysis that GS4-GFP could transduce each glioma cell line. We 106 
further studied the replication kinetics of GS4-GFP in each glioma cell line by initially mixing 5% 107 
infected glioma cells with 95% uninfected glioma cells, and examining horizontal transmission of 108 
GFP expression over time. Flow-cytometric analysis showed that GS4-GFP could efficiently 109 
transduce each glioma cell line, and spread throughout the entire cell population within 8 days in the 110 
case of human U-87 cells, and within 14 days in the case of rat RG-2 and CNS-1 cells (Figure 2A). 111 
 112 
Figure 1. Structure of GALV-RRV carrying transgenes. Each GALV-RRV contains an IRES-GFP, IRES-113 
CD or IRES-NTR gene expression cassette inserted between GALV env and the 3’ UTR. Ψ, packaging 114 
signal. LTR, long terminal repeat. 115 
 116 
Figure 2. Replicative spread of GS4-GFP in glioma cells in culture and in intracerebral gliomas in vivo. 117 
(A) GS4-GFP-transduced RG-2 cells (5%) and uninfected RG-2 cells (95%) were mixed and seeded 118 
onto culture plates. At various time points after cell mixing, the cell populations were analyzed for 119 
GFP expression. X-axis: days after cell mixture. Y-axis: % of cells expressing GFP. (B) GS4-GFP (2×104 120 
TU) was injected into a pre-established intracerebral RG-2 tumor model in Fischer 344 rats. The spread 121 
of GS4-GFP in tumors was examined by quantification of GFP expression at 13 (n=6) and 19 days (n=3) 122 
after viral vector inoculation. 123 
2.2. Efficient and progressive spread of GALV-RRV in an intracerebral glioma model. 124 
We evaluated the ability of GALV-based RRV to achieve a high level of transduction in gliomas 125 
in vivo by testing the GS4-GFP vector in an intracerebral RG-2 tumor model. A single dose of 2×104 126 
transducing units (TU) of GS4-GFP was injected into pre-established intracerebral RG-2 tumors in 127 
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syngeneic Fischer 344 rats. At two time points after vector injection, intratumoral spread of GS4-GFP 128 
was evaluated by flow-cytometric analysis of excised intracerebral tumors. On day 13 post-vector 129 
injection, the percentage of GFP-positive RG-2 tumor cells averaged 62.0±16.4%, and by day 19 post-130 
vector injection, this had increased to 94.2±2.8% (P<0.01), demonstrating that GS4-GFP spread 131 
efficiently and progressively in orthotopic intracerebral rat gliomas (Figure 2B). 132 
2.3. No detectable spread of GALV-RRV to extratumoral tissues. 133 
To detect any possible GALV-RRV spread to extratumoral tissues, real-time PCR assay of 134 
genomic DNA extracted from various extratumoral organs was performed using primers specific for 135 
the GALV env (Table 1). This assay could detect down to 50 copies of the GALV provirus per 5×104 136 
cell genomes, representing a transduction level of approximately 0.1%. As expected, GALV sequence 137 
could be readily detected in GS4-GFP-transduced glioma tissues (n=3; 19 days after viral vector 138 
injection). However, no detectable spread was observed in any of the extratumoral organs examined 139 
from the same GS4-GFP-injected animals. 140 
Table 1. Biodistribution of GS4-GFP after intratumoral injection of the vector in immune-competent 141 
intracerebral glioma model. 142 
 Copies of GALV env per cell 
tumor 1.46 ± 0.23 
contralateral normal brain − 
bone marrow − 
spleen − 
intestine − 
liver − 
Genomic DNA extracted from intracerebral glioma and extratumoral organs of GS4-143 
GFP-infected rats was analyzed by real-time PCR assay. The numbers of GALV env 144 
copies per cell are presented as means ± standard deviations. −, not detectable 145 
(detection limit was 0.001 copy per cell). 146 
 147 
2.4. Dose-dependent cytotoxicity of RRV-transduced cells after prodrug administration. 148 
To examine the ability of RRV to deliver prodrug activator genes, GS4-CD- and GS4-NTR-149 
transduced RG-2 cells were first treated with their respective prodrugs, 5-FC and CB1954, at various 150 
concentrations. To distinguish the cytotoxic effects of prodrug activator gene function from any 151 
potential nonspecific toxicity due to the prodrugs themselves, GS4-GFP-transduced cells were also 152 
treated with each prodrug at the corresponding concentrations as experimental controls. The 5-FC 153 
and CB1954 prodrugs showed negligible cytotoxicity at concentrations of ≤1 mM and ≤0.25 μM, 154 
respectively.  155 
Infection with GS4-CD or GS4-NTR resulted in potent killing of RG-2 cells exposed to the 156 
corresponding prodrug at all concentrations tested, and the degree of cytotoxicity was highly 157 
prodrug concentration-dependent (Figure 3). Exposing GS4-CD-transduced cells to 5-FC at 0.04 mM 158 
led to a dramatic drop in cell viability to ~30% relative to the control group. Similarly, exposing GS4-159 
NTR-transduced cells to CB1954 at 0.1 μM induced the same degree of cytotoxicity, indicating that 160 
the NTR/CB1954 enzyme prodrug system might also be useful if delivered in the context of RRV to 161 
inhibit tumors and prolong survival. 162 
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 163 
Figure 3. In vitro cytotoxicity achieved by GALV-based RRV plus prodrug treatment. (A) GS4-CD- 164 
and GS4-GFP-transduced RG-2 cells were exposed to 5-FC ranging from 0 to 1 mM, and cell viability 165 
was determined 3 days later by MTS assay. (B) GS4-NTR- and GS4-GFP-transduced RG-2 cells were 166 
exposed to CB1954 ranging from 0 to 0.25 μM, and cell viability was determined 3 days later by MTS 167 
assay. *, P<0.005. 168 
2.5. RRV-mediated prodrug activator gene delivery significantly improves survival of immune-competent 169 
rats bearing gliomas.   170 
We determined whether the high in vivo tumor transduction levels achieved by GALV-RRV has 171 
the potential to improve survival by evaluating prodrug activator gene therapy using GS4-CD and 172 
GS4-NTR in the intracerebral RG-2 glioma model. After establishing intracerebral RG-2 gliomas by 173 
stereotactic implantation, the GS4-CD or GS4-NTR vector was inoculated via intratumoral injection, 174 
as above. Treatment with the GS4-CD vector, followed by a single cycle of 5-FC administered by 175 
intraperitoneal injection, resulted in a survival advantage with a median survival time of 22 days, as 176 
compared to a median survival time of 19 days in the control group treated with the GS4-GFP vector 177 
and 5-FC (P<0.05) (Figure 4A). Treatment with the GS4-NTR vector followed by two doses of CB1954 178 
administration also resulted in a significant survival advantage, with a median survival time of 179 
30 days, compared to the median survival time of 17.5 days in the control group (P<0.05) (Figure 4B).  180 
 181 
Figure 4. Survival analysis of immune-competent rats bearing intracerebral RG-2 gliomas. (A) GS4-182 
CD or GS4-GFP was stereotactically injected into pre-established intracerebral RG-2 tumors three 183 
days after tumor inoculation. Eight days after viral vector inoculation, the rats received 184 
intraperitoneal injections of 5-FC (100 mg/kg), once every other day, for a total of 7 treatments. 185 
Survival curves were constructed for two treatment groups: GS4-CD plus 5-FC, and GS4-GFP plus 5-186 
FC. (B) GS4-NTR was stereotactically injected into pre-established intracerebral RG-2 tumors three 187 
days after tumor inoculation. Seven and eight days after viral vector inoculation, the rats received 188 
daily intraperitoneal injections of CB1954 (2.5 mg/kg) or PBS. Survival curves were constructed for 189 
two treatment groups GS4-NTR plus CB1954 and GS4-NTR plus PBS. 190 
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2.6. MicroPET imaging of RG-2 glioma-bearing rats after prodrug activator gene therapy. 191 
Our previous study reported that O-2-[18F]fluoroethyl-L-tyrosine (L-[18F]FET) microPET was 192 
superior to [18F]FDG microPET for the monitoring of brain tumor due to the low uptake of L-[18F]FET 193 
in normal brain [29]. MicroPET imaging of glioma-bearing rats using L-[18F]FET revealed sizable RG-194 
2 gliomas at the tumor implantation site in the group treated with GS4-NTR alone (Figure 5B). A clear 195 
difference between tumor-implanted and normal brains was observed. In contrast, rats treated with 196 
GS4-NTR plus CB1954 showed smaller tumors remaining at the tumor implantation site, 197 
demonstrating the therapeutic benefit achieved by GALV-based RRV-mediated prodrug activator 198 
gene therapy (Figure 5C). 199 
 200 
Figure 5. MicroPET imaging of intracerebral RG-2 glioma-bearing rats. MicroPET imaging of L-201 
[18F]FET in rats was performed using the R4 system, 20 days after intracerebral RG-2 glioma 202 
implantation. Representative examples comparing microPET imaging results from non-tumor-203 
bearing rats (A), tumor-bearing rats treated with GS4-NTR but without prodrug administration (B), 204 
or tumor-bearing rats with GS4-NTR and CB1954 prodrug treatments (C) are shown, and tumor 205 
regions are indicated by arrowheads. The tumor uptake of L-[18F]FET in the GS4-NTR − CB1954 group 206 
relative to the GS4-NTR + CB1954 group was 2.015-fold (P<0.01). 207 
3. Discussion 208 
Persistent nonlytic infection of tumor cells by RRV facilitates the widespread seeding of prodrug 209 
activator genes, thereby allowing synchronized cell killing triggered by prodrug administration. 210 
Using GALV-based RRV expressing the CD and NTR suicide genes followed by the administration 211 
of the prodrugs 5-FC and CB1954, we have achieved highly efficient killing of glioma cells both in 212 
culture and in vivo, resulting in significantly prolonged survival in an immune-competent 213 
intracerebral glioma model. 214 
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In addition to the significant survival improvement achieved by GALV-based RRV-mediated 215 
CD prodrug activation therapy, here we also demonstrate a significant tumor inhibitory effect on 216 
intracerebral RG-2 tumors after GS4-NTR-mediated prodrug activation therapy. Of note, the E. coli 217 
NTR isoform B (NfsB) gene cloned into the GS4-NTR vector expresses an enzyme that actively 218 
converts CB1954 to a 4-hydroxylamino derivative that is subsequently converted into a potent 219 
cytotoxic bifunctional alkylating agent capable of cross-linking DNA and therefore achieving cell-220 
cycle-independent killing of both actively proliferating and non-proliferating cells [30].  221 
However, despite significant increases in survival, all animals did succumb to tumor burden. 222 
Factors which may have contributed to the lack of eradication of tumor burden and potential avenues 223 
for improvement include the vector dose and/or the schedule of prodrug delivery. In vivo vector 224 
replication and spread was assessed with approximately 60% of tumor cells positive for GFP 225 
expression (vector) 13 days post vector administration. In this study the animals were treated with 226 
prodrug beginning day 7 (NTR) or day 8 (CD), where the number of tumor cells transduced would 227 
be less than 60%. Increasing the vector dose and hence the number of cells transduced at the time of 228 
prodrug administration may increase the survival benefit. 229 
Here we have validated both CD and NTR as effective prodrug activator genes in the context of 230 
GALV-RRV. As noted, the different cytocidal effects caused by CD/5-FC and NTR/CB1954 would 231 
allow us to employ combination prodrug activation therapy, analogous to combination 232 
chemotherapy, but generated directly within the tumor itself, thereby avoiding adverse effects of 233 
systemic chemotherapy. However, for optimal combined gene therapy with both prodrug activator 234 
genes, these genes must be delivered using RRV with different envelopes in order to avoid receptor 235 
interference. Since MLV-RRV and GALV-RRV utilize different cellular receptors (PiT-2 and PiT-1 236 
phosphate transporters, respectively) for viral entry [17], co-infection of glioma cells with both 237 
vectors supplied with different prodrug activator genes may be employed to achieve synergistic 238 
cytotoxic effects, thus augmenting the efficacy of gene therapy [18,22]. Now that the present studies 239 
have validated the use of GALV-RRV expressing NTR as a single-agent prodrug activator vector in 240 
itself, in future studies we can proceed to evaluate combination prodrug activator gene therapy 241 
together with the current clinical vector, CD-armed MLV-RRV. 242 
Real-time PCR analysis demonstrated that the replication of GALV-RRV is highly restricted to 243 
the tumor itself, with no spread to ectopic sites such as bone marrow and spleen detectable in 244 
immune-competent glioma models. This result is consistent with our previous study showing that 245 
MLV-RRV delivered to intracerebral RG-2 tumors in immune-competent syngeneic hosts showed no 246 
detectable spread to all normal tissues examined [13]. Our inability to detect RRV in extratumoral 247 
tissues suggests that, although impaired innate and adaptive immunity in cancer cells enable 248 
progressive replicative spread of the virus within tumors even in an immune-competent host [31,32], 249 
these mechanisms remain intact in normal tissues and prevent systemic RRV dissemination. Of 250 
course, it is possible that low levels of systemic RRV dissemination might occur below the detection 251 
limit of our PCR assay, and the potential for retroviral vectors to cause insertional mutagenesis that 252 
can contribute to the development of malignancies remains a concern [33-35]. However, when 253 
considering the use of RRV as an agent for cancer therapy, this concern is alleviated, as incorporation 254 
of prodrug activator genes not only arms the vector against cancer cells, but also helps to eliminate 255 
inadvertently transduced normal cells that might become transformed. Furthermore, as an additional 256 
safety mechanism, various antiretroviral drugs such as 3'-azido-3'-deoxythymidine (AZT) could be 257 
used to effectively block retroviral replication and dissemination. It should be noted however that, to 258 
date, more than 300 patients with recurrent high-grade glioma have been treated with CD-armed 259 
MLV-RRV in multiple Phase I dose escalation trials (NCT01156584, NCT01470794, NCT01985256) 260 
and an international Phase III trial (NCT02414165), and there have been no such severe adverse effects 261 
related to malignant transformation. Certainly, clinical development of GALV-RRV will require 262 
further confirmation of preclinical safety, biodistribution and therapeutic efficacy. Nonetheless, given 263 
the extremely poor prognosis of patients with GBM, the use of RRV may represent a promising 264 
treatment strategy, particularly if the therapeutic benefits outweigh the potential risks, as indicated 265 
by our current results. 266 
 267 
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4. Materials and methods 268 
4.1. Viral vectors and cell lines. 269 
As described previously, plasmid pGS4-GFP [28] encodes a replication-competent GALV vector, 270 
in which an IRES-GFP gene cassette has been inserted between GALV env and the 3’ UTR. The CD 271 
and NTR genes were amplified from plasmid pACE-CD [12] and E. coli genomic DNA by PCR, and 272 
used to replace the GFP sequence in pGS4-GFP, generating plasmids pGS4-CD and pGS4-NTR, 273 
respectively. The primer sequences used for PCR amplification of the E. coli NTR gene (isoform B) 274 
are 5’-atggatatcatttctgtcgcct-3’ and 5’-ttacacttcggttaaggtgatgtt-3’ [36]. The transformed human 275 
embryonic kidney cell line 293T [37], U-87 human glioma cells (obtained from the American Type Culture 276 
Collection), and RG-2 and CNS-1 rat glioma cells were grown in Dulbecco’s modified Eagle’s medium 277 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen). Viral vectors 278 
were produced by transient transfection of 293T cells with plasmid pGS4-GFP, pGS4-CD or pGS4-279 
NTR using Lipofectamine 2000 Reagent (Invitrogen). For in vitro transduction experiments, 4 μg/ml 280 
polybrene (Sigma, St. Louis, MO) was added to the culture medium at the time of infection. Titer 281 
determination was performed on target cells in the presence of AZT (Sigma) to prevent secondary 282 
vector replication, as described previously [38]. Virus titers were represented as transducing units 283 
(TU)/ml. 284 
4.2. Viral vector replication assays in glioma cells.  285 
Glioma cells at 20-25% confluency in six-well plates were grown in fresh medium containing 286 
GS4-GFP virus stock at low MOI. At various time points post-infection, the cells were analyzed for 287 
GFP expression by flow cytometry. This procedure was performed to ensure that the entire cell 288 
population exhibited GFP fluorescence. Infection of GS4-CD and GS4-NTR to RG-2 cells was 289 
performed in parallel until full transduction was achieved. In a separate experiment, GS4-GFP-290 
transduced glioma cells were mixed with uninfected glioma cells at a proportion of 5% of the total 291 
cell population and seeded onto six-well plates. At various time points post-infection, the cell 292 
populations were analyzed for GFP expression. 293 
4.3. Viral vector replication assay in intracerebral glioma model. 294 
Intracerebral RG-2 gliomas were established by stereotactic injection of 5×104 RG-2 cells into the 295 
right frontal lobe in Fischer 344 rats (National Laboratory Animal Center, Taipei, Taiwan) as 296 
described previously [13]. Three days later, the rats were stereotactically injected with 2×104 TU of 297 
GS4-GFP at the tumor implantation site. At various time points after viral vector transduction, the 298 
rats were sacrificed and the tumors were excised and digested with collagenase (Invitrogen). The 299 
dissociated cells were filtered through 100-μm cell strainers, pelleted by centrifugation, resuspended 300 
in culture medium containing 50 μM AZT, and plated onto culture plates. After overnight culture, 301 
the cells were trypsinized and immediately subjected to flow cytometry for GFP expression analysis. 302 
4.4. Real-time PCR analysis. 303 
To detect any integrated GALV-RRV sequence in tissue genomes, real-time PCR was performed 304 
as described previously [19,39] using an ABI Prism 7700 sequence detector. The primers 5’-305 
cctattactcctccttctgttg-3’ and 5’-gggcctgatatttttgtctaag-3’ were designed to target GALV env. 306 
Apolipoprotein B gene for precise amounts of input genomic DNA were also quantified as an internal 307 
control (primers: 5’-cacgtgggctccagcatt-3’ and 5’-tcaccagtcatttctgcctttg-3’). Real-time PCR was done 308 
in 25 μl of reaction mixture containing genomic DNA, 12.5 μl of 2X SYBR green real-time PCR master 309 
mix (Toyobo, Osaka, Japan) and 300 nM of each primer. Products were amplified by 35 cycles of 310 
successive incubation at 95°C for 15 sec and at 60°C for 1 min. A standard curve for GS4-GFP copy 311 
number was generated by amplification of serially diluted GS4-GFP plasmid template at specific copy 312 
numbers mixed into genomic DNA from uninfected rat cells. 313 
 314 
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4.5. In vitro cytotoxicity assay.   315 
GS4-GFP-, GS4-CD- and GS4-NTR-transduced RG-2 cells were seeded onto replicate 96-well 316 
plates (2000 cells/well), cultured overnight, and exposed to 5-FC (Sigma) or CB1954 (Sigma) at various 317 
concentrations. Cell viability was determined 3 days later by MTS assay using the CellTiter Aqueous 318 
One Solution Cell Proliferation Assay kit (Promega, Madison, WI). 319 
4.6. Survival assay using intracerebral glioma models. 320 
The GS4-CD and GS4-NTR viral vectors (2×104 TU) was injected 3 days after intracerebral tumor 321 
implantation (5×104 RG-2 cells) in Fischer 344 rats. Eight days after GS4-CD vector injection, 322 
intraperitoneal injections of 5-FC (100 mg/kg) were performed, once every other day, for a total of 7 323 
treatments. For the GS4-NTR group, CB1954 (2.5 mg/kg) was injected intraperitoneally 7 and 8 days 324 
after vector injection. 325 
4.7. MicroPET imaging. 326 
L-[18F]FET microPET imaging of tumor-bearing rats was performed 20 days after RG-2 327 
implantation using the R4 system (Concorde Microsystems, Knoxville, TN) as described previously 328 
[29]. Static images were acquired 60 min after the intravenous injection of 3.7 MBq of L-[18F]FET in 329 
the rats. 330 
4.8. Statistical analysis. 331 
Student’s t-test was used for statistical analysis of in vitro cytotoxicity results. Kaplan-Meier 332 
analysis and log-rank tests were used to evaluate survival. All analyses were conducted using SAS 333 
software (SAS Institute, Cary, NC). 334 
 335 
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